Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06984822

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06984822
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06984822. Non-randomized; no masking; primary purpose prevention. Start 2025-08-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Acronym
BiomarkerOCT
Condition
Diabetic Macular Edema
Condition
Visual Impairment
Condition
Diabetes Mellitus
Condition
Hyperglycaemia (Diabetic)
Condition
Oxidative Stress
Condition
Vascular Endothelial Growth Factor
Condition
VEGF
Intervention (Drug)
Anti-VEGF treatment
Intervention (Device)
Dexamethasone implant
Intervention (Other)
Treatment with intravitreal anti-VEGF OR Dexamethasone implant
Lead sponsor
Vastra Gotaland Region (class: other government)

Record details

Record id
cardio:ct-nct06984822
Content hash
a63e3cd952556b365db4ae7b9997c9d47cde52bd27c0484b8c2e5052e6e74906